Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude's heart valve repair devices

This article was originally published in Clinica

Executive Summary

The Tailor Flexible Ring and Tailor Flexible Band, two devices developed by St Jude Medical for the repair of the heart's mitral and tricuspid valves, have been approved in Japan. When valves become diseased or damaged, the shape of the annulus the fibrous ring that surrounds the opening of heart valves can change. This causes the valve's leaflets to become misaligned, preventing the valve from closing tightly. St Jude's devices support the valve accommodating the natural movement of the annulus. In 2005, the number of valve repair procedures performed in Japan increased more than 20% from the prior year, to nearly 6,400 (according to statistics reported in the September 2007 issue of General Thoracic and Cardiovascular Surgery). The Japanese regulators also granted reimbursement approval. The St Paul, Minnesota firm intends to launch the products immediately; they are already launched in the US and Europe.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel